CN105326952A - Medicine composition for treating acute cholecystitis - Google Patents
Medicine composition for treating acute cholecystitis Download PDFInfo
- Publication number
- CN105326952A CN105326952A CN201510944971.6A CN201510944971A CN105326952A CN 105326952 A CN105326952 A CN 105326952A CN 201510944971 A CN201510944971 A CN 201510944971A CN 105326952 A CN105326952 A CN 105326952A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- pharmaceutical composition
- medicine
- acute cholecystitis
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine composition and application thereof, in particular to a medicine composition for treating acute cholecystitis and application thereof, and belongs to the technical field of medicine. The medicine composition is prepared from medicine active components including fructus forsythiae, medicinal magnolia bark slices stir-baked with ginger juice, paeonia suffruticosa, angelica sinensis, dandelion, Japanese climbing fern spore, folia perillae acutae and cape jasmine. The components are applied in a compatibility mode, and the treatment effect of the medicine composition for acute cholecystitis is enhanced in a synergetic mode. The medicine composition has an exact effect when treating acute cholecystitis and has wide medical application prospects.
Description
Technical field
The present invention relates to a kind of medical composition and its use, relate to a kind of medical composition and its use being used for the treatment of acute cholecystitis specifically, belong to medical art.
Background technology
Acute cholecystitis is the acute suppurative inflammation of gallbladder, and 80% with cholelithiasis, is one of clinical common acute abdomen.Cause the common cause of primary disease to comprise: calculus cause at cystic duct incarceration block, intracapsular bile of gallbladder smoulders, concentrated cholate infringement mucous membrane of gallbladder causes inflammation; Bacteriological infection, common pathogenic bacterium are escherichia coli, aerobacteria, bacillus pyocyaneus etc., mostly drive in the wrong direction from biliary tract; Chemical stimulation: high concentration bile salt stimulates mucous membrane of gallbladder to cause acute inflammation.Often occur in wound, or some abdominal postoperatives irrelevant with gallbladder system.Its main clinical manifestation comprises heating, the acute tenderness of upper right abdomen, during palpation, or enclosed mass can be touched herein, the visible leukocytosis of case control, gallbladder diffuse inflammation reaction or downright bad.Even within short-term, there is the life-threatening complication such as dehydration, shock in the patient be in a bad way.Clinically operative treatment and expectant treatment are divided into for the treatment of acute cholecystitis at present, expectant treatment takes effect slowly, even occur that patient transfers chronic cholecystitis to, but operative treatment is for there being invasive procedures, post-operative complication such as infection of incisional wound, pulmonary infection and adhesive ileus happen occasionally, and bring certain obstruction to patient's post-operative recovery.
Acute cholecystitis, the category of the disease such as " hypochondriac pain ", " gallbladder-distention " that according to its clinical manifestation analysis, Chinese medicine is belonged to.Clinical syndrome differentiation many genus dampness-heat in the liver and gallbladder, stagnation of QI due to depression of the liver and stagnation of liver-QI with deficiency of the spleen etc., over the course for the treatment of by understanding the cause of disease, determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, to alleviate or to eliminate the symptom of patient, evident in efficacy, clinic is promoted, but its definite mechanism of action Exploring.
Summary of the invention
In order to solve the shortcoming of existing treatment acute cholecystitis disease in clinical practice, the invention provides a kind of evident in efficacy, cheap, the pharmaceutical composition that side effect is little, its active constituents of medicine is made up of following traditional Chinese medicines: Fructus Forsythiae, Cortex Magnoliae Officinalis(processed with ginger), Cortex Moutan, Radix Angelicae Sinensis, Herba Taraxaci, Spora Lygodii, Folium Perillae, Fructus Gardeniae.
The primary efficacy of further each component is as follows:
Fructus Forsythiae, bitter, be slightly cold.Return lung, the heart, small intestine meridian.Heat-clearing and toxic substances removing, dispersing swelling and dissipating binds.For carbuncle, scrofula, acute mastitis, erysipelas, anemopyretic cold, epidemic febrile disease from the beginning of, warmly join the army, high hot excessive thirst, coma sends out speckle, pyretic stranguria urine retention.
Cortex Magnoliae Officinalis(processed with ginger): get Cortex Magnoliae Officinalis silk, according to stir-frying with ginger juice method (appendix II D) fried dry.This product is bending strand shape, and section fibrous, in puce.Bitter, pungent, temperature.Return spleen, stomach, lung, large intestine channel.Dampness expectorant, the therapeutic method to keep the adverse QI flowing downwards is except full.For humidity hysteresis damaging the spleen and stomach, gastral cavity painful abdominal mass is vomited and diarrhoea, and stagnation of QI due to dyspepsia, abdominal distention constipation, phlegm retention is breathed with cough.
Cortex Moutan, bitter, pungent, be slightly cold.GUIXIN, liver, kidney channel.Clearing away heat and cooling blood, blood circulation promoting and blood stasis dispelling.For maculae caused by violent heat pathogen, hematemesis and epistaxis, night fever abating at dawn, lossless hectic fever due to YIN-deficiency, amenorrhea dysmenorrhea, carbuncle sore tumefacting virus, falls and flutters the pain of injury.
Radix Angelicae Sinensis, sweet, acrid, warm.Return liver, the heart, spleen channel.Enrich blood and invigorate blood circulation, menstruction regulating and pain relieving, loosening bowel to relieve constipation.For blood deficiency and yellow complexion, dizzy cardiopalmus, menoxenia, amenorrhea dysmenorrhea, asthenia cold abdominalgia, dryness of the intestine constipation, rheumatic arthralgia, injury from falling down, ulcer sores.
Herba Taraxaci, bitter, sweet, cold.Return liver, stomach warp.Heat-clearing and toxic substances removing, dispersing swelling and dissipating binds, inducing diuresis for treating stranguria syndrome.For furuncle swelling toxin, acute mastitis, scrofula, conjunctival congestion, pharyngalgia, lung abscess, acute appendicitis, jaundice due to damp-heat, the puckery pain of pyretic stranguria.
Spora Lygodii is sweet, salty, cold.Return bladder, small intestine meridian.Eliminating damp-heat, treating stranguria pain relieving.For pyretic stranguria, sand Stranguria, stranguria caused by urinary stone, stranguria with blood, stranguria marked by chyluria, Urethra astringent pain.
Folium Perillae, pungent, temperature.Return lung, spleen channel.Induce sweat cold expelling, relieving QI stagnancy in the stomach.For anemofrigid cold, cough vomiting and nausea, vomiting during pregnancy, fish Eriocheir sinensis is poisoning.
Fructus Gardeniae, bitter, cold.GUIXIN, lung, tri-jiao channel.Fruit: pathogenic fire purging relieving restlessness, clearing away heat and promoting diuresis, removing pathogenic heat from blood and toxic substance from the body.Vexed for calentura, jaundice dark coloured urine, blood strangury and dry pain, heat in blood tells nosebleed, conjunctival congestion and swelling pain, pathogenic fire,toxin and furuncles; External treatment bruise pain.Root: eliminating fire and detoxication, clearing away heat-damp and promoting diuresis, cool the blood dissipate blood stasis.For infectious hepatitis, traumatic injury, acute toothache.
One of the object of the invention is to provide a kind of pharmaceutical composition being used for the treatment of acute cholecystitis.The rigorous prescription of pharmaceutical composition of the present invention, compatibility is reasonable, and full side interacts, and plays the special effect of clearing away heat-damp and promoting diuresis, promoting the circulation of QI to relieve pain, dispersing swelling and dissipating binds altogether, and treatment acute cholecystitis achieves beyond thought therapeutic effect.Experiment proves, drug combination can strengthen the therapeutic effect of medicine, reduces adverse effect.Based on this, the weight proportion of the present invention is preferred this pharmaceutical composition each component is: Fructus Forsythiae 10-20 weight portion, Cortex Magnoliae Officinalis(processed with ginger) 2-8 weight portion, Cortex Moutan 5-15 weight portion, Radix Angelicae Sinensis 16-25 weight portion, Herba Taraxaci 6-12 weight portion, Spora Lygodii 2-6 weight portion, Folium Perillae 2-10 weight portion, Fructus Gardeniae 2-10 weight portion.Most preferably, the parts by weight of each Chinese medicine of described pharmaceutical composition are: Fructus Forsythiae 15 weight portion, Cortex Magnoliae Officinalis(processed with ginger) 5 weight portion, Cortex Moutan 10 weight portion, Radix Angelicae Sinensis 20 weight portion, Herba Taraxaci 9 weight portion, Spora Lygodii 4 weight portion, Folium Perillae 6 weight portion, Fructus Gardeniae 6 weight portion.
Present invention also offers the preparation method of pharmaceutical composition active component, specifically comprise following steps: get each medical material, be ground into coarse powder respectively; Add water warm macerating 2 hours, decocts twice, each 2 hours, merges decoction liquor, filters; When filtrate is concentrated into 80 DEG C, relative density is the clear paste of 1.11 ~ 1.16, slowly adds ethanol, make alcohol content reach 75% when being chilled to 40 DEG C, stir, leave standstill 12 hours, filter, reclaim ethanol extremely without alcohol taste, filtrate adds appropriate amount of auxiliary materials, and technique is prepared and be get final product routinely., to obtain final product.
In the pharmaceutical composition for the treatment of acute cholecystitis of the present invention, when it is used for the treatment of acute cholecystitis, suitable route of administration can be selected according to the state of an illness and pharmaceutical properties, be preferably oral administration.Be used for the treatment of or prevent the form of administration of acute cholecystitis to be the present invention's pharmaceutical preparation described above, as tablet, capsule, slow releasing capsule, slow releasing tablet, suspensoid.Preferably tablet.
Described tablet is that pharmaceutical composition active component adds the granulation of pharmaceutically acceptable adjuvant, dry, adds mix lubricant tabletting and forms.
Described pharmaceutically acceptable adjuvant is filler, disintegrating agent and lubricant.
Described filler is one or more in lactose, dextrin and mannitol.
Described disintegrating agent is one or both in sodium carboxymethyl cellulose and carboxymethyl starch sodium.
Described lubricant is one or more in magnesium stearate, sodium stearyl fumarate and micropowder silica gel.
Above-mentioned containing in the pharmaceutical preparation of active ingredient of Chinese herbs, each daily dose is 1g-2g, takes at twice.
Based on pharmacodynamics embodiment of the present invention, the present invention also asks to protect the purposes of aforementioned pharmaceutical compositions in preparation acute cholecystitis medicine.Oral administration is preferably during aforementioned pharmaceutical compositions administration.As shown in the embodiment of the present invention 6, can find out: pharmaceutical composition of the present invention has positive therapeutical effect.Be embodied in: test a group has significant difference respectively compared with test b-d group, significant synergism is there is in this after showing each component compatibility of pharmaceutical composition of the present invention, not only significantly strengthen on medication effect, and untoward reaction is little, safety coefficient is high, is conducive to clinical application.
Detailed description of the invention
The present invention is further illustrated below by way of specific embodiment; but those skilled in the art should know specific embodiments of the invention and not limit the present invention in any way, and any equivalent replacement done on basis of the present invention all falls into protection scope of the present invention.
Prepared by embodiment 1 medicinal composition tablets
Preparation technology:
The preparation of active component:
In prescription, the parts by weight of each Chinese medicine are: Fructus Forsythiae 15 weight portion, Cortex Magnoliae Officinalis(processed with ginger) 5 weight portion, Cortex Moutan 10 weight portion, Radix Angelicae Sinensis 20 weight portion, Herba Taraxaci 9 weight portion, Spora Lygodii 4 weight portion, Folium Perillae 6 weight portion, Fructus Gardeniae 6 weight portion.
Get each medical material, be ground into coarse powder respectively; Add water warm macerating 2 hours, decocts twice, each 2 hours, merges decoction liquor, filters; When filtrate is concentrated into 80 DEG C, relative density is the clear paste of 1.11 ~ 1.16, slowly adds ethanol, make alcohol content reach 75%, stir when being chilled to 40 DEG C, leaves standstill 12 hours, filters, and reclaims ethanol to the active component without alcohol taste, to obtain final product.
The active component taking recipe quantity adds lactose and sodium carboxymethyl cellulose granulation, and granulated by 16 mesh sieves, less than 60 DEG C dry.After completing after drying, use 20 mesh sieve carries out granulate, sifts out the fine powder in dry granular, mixes, tabletting, to obtain final product with the magnesium stearate of sieving.
Prepared by embodiment 2 medicinal composition tablets
Preparation technology:
The preparation of active component:
In prescription, the parts by weight of each Chinese medicine are: Fructus Forsythiae 10 weight portion, Cortex Magnoliae Officinalis(processed with ginger) 2 weight portion, Cortex Moutan 5 weight portion, Radix Angelicae Sinensis 16 weight portion, Herba Taraxaci 6 weight portion, Spora Lygodii 6 weight portion, Folium Perillae 2 weight portion, Fructus Gardeniae 2 weight portion.
Get each medical material, be ground into coarse powder respectively; Add water warm macerating 2 hours, decocts twice, each 2 hours, merges decoction liquor, filters; When filtrate is concentrated into 80 DEG C, relative density is the clear paste of 1.11 ~ 1.16, slowly adds ethanol, make alcohol content reach 75%, stir when being chilled to 40 DEG C, leaves standstill 12 hours, filters, and reclaims ethanol to the active component without alcohol taste, to obtain final product.
The active component taking recipe quantity adds lactose and carboxymethyl starch sodium granulation, and granulated by 16 mesh sieves, less than 60 DEG C dry.After completing after drying, use 20 mesh sieve carries out granulate, sifts out the fine powder in dry granular, mixes, tabletting, to obtain final product with the magnesium stearate of sieving.
Prepared by embodiment 3 medicinal composition tablets
Preparation technology:
The preparation of active component:
In prescription, the parts by weight of each Chinese medicine are: Fructus Forsythiae 20 weight portion, Cortex Magnoliae Officinalis(processed with ginger) 8 weight portion, Cortex Moutan 15 weight portion, Radix Angelicae Sinensis 25 weight portion, Herba Taraxaci 12 weight portion, Spora Lygodii 2 weight portion, Folium Perillae 10 weight portion, Fructus Gardeniae 10 weight portion.
Get each medical material, be ground into coarse powder respectively; Add water warm macerating 2 hours, decocts twice, each 2 hours, merges decoction liquor, filters; When filtrate is concentrated into 80 DEG C, relative density is the clear paste of 1.11 ~ 1.16, slowly adds ethanol, make alcohol content reach 75%, stir when being chilled to 40 DEG C, leaves standstill 12 hours, filters, and reclaims ethanol to the active component without alcohol taste, to obtain final product.
The active component taking recipe quantity is granulated on mannitol and carboxymethyl starch sodium, is granulated by 16 mesh sieves, and less than 60 DEG C dry.After completing after drying, use 20 mesh sieve carries out granulate, sifts out the fine powder in dry granular, mixes, tabletting, to obtain final product with the magnesium stearate of sieving.
Prepared by embodiment 4 medicinal composition tablets
Preparation technology:
The preparation of active component:
In prescription, the parts by weight of each Chinese medicine are: Fructus Forsythiae 25 weight portion, Cortex Magnoliae Officinalis(processed with ginger) 12 weight portion, Cortex Moutan 12 weight portion, Radix Angelicae Sinensis 5 weight portion, Herba Taraxaci 10 weight portion, Spora Lygodii 15 weight portion, Radix Polygalae 12 weight portion, Fructus Gardeniae 20 weight portion.The other the same as in Example 1.
Prepared by embodiment 5 medicinal composition tablets
Preparation technology:
The preparation of active component:
In prescription, the parts by weight of each Chinese medicine are: Cortex Magnoliae Officinalis(processed with ginger) 10 weight portion, Cortex Moutan 12 weight portion, Radix Angelicae Sinensis 15 weight portion, Herba Taraxaci 12 weight portion, Pheretima 10 weight portion, Fructus Gardeniae 15 weight portion.
The other the same as in Example 1.
The clinical observation test of embodiment 6 pharmaceutical composition of the present invention
1. physical data:
This test example chooses 160 routine acute cholecystitis patients for object of study, involving acute cholecystitis diagnostic criteria that Western medicine diagnose meets " practical internal medicine " (Chen Haozhu, People's Health Publisher, 2002); Dependent diagnostic standard during tcm diagnosis meets " new Chinese medicine guideline of clinical investigations ", and dialectical be liver gallbladder damp-heat type, disease is seen: right flank rib, right Upper abdominal pain, paroxysm aggravation, tenderness, body has cold and heat or fever without chill, yellow urine constipation, or double icteric sclera skin is yellow, yellowish fur, stringy and rolling pulse number.
Be divided into each 40 examples of test a, b, c, d group at random.Wherein test a group man 22 example, female 18 example; Age 20-59 year, year mean age (40.2 ± 1.12); Course of disease 2h-11d, average course of disease (6.2 ± 0.52) d.Test b group man 25 example, female 15 example; Age 21-58 year, year mean age (41.5 ± 0.60); The shortest 3h-10d of the course of disease, average course of disease (6.3 ± 0.55) d.Test c group man 24 example, female 16 example; Age 21-55 year, year mean age (41.0 ± 1.60); Course of disease 3h-11d, average course of disease (6.0 ± 0.50) d.Test d group man 23 example, female 17 example; Age 23-56 year, year mean age (41.5 ± 1.58); Course of disease 20h-10d, average course of disease (6.1 ± 0.50) d.Four groups of sexes, age, the state of an illness, courses of disease etc. compare, and difference there are no significant meaning (P > 0.05), has comparability.
2. exclusion standard
1) patient that treatments period compliance is poor, take the treatment of its medicine or drop by the wayside is got rid of;
2) severe complication such as perforation of gallbladder and septicemia, serious hepatic renal dysfunction person is got rid of;
3) get rid of and there is mental disorder, mental maladjustment, can not the patient of partner treatment;
4) patient medication being existed to severe allergic reaction is got rid of;
5) trimester of pregnancy, breast-feeding female is got rid of.
3. process of the test:
Test a group: take tablet prepared by embodiment 1, every sheet contains crude drug amount 0.25g, each 2-4 sheet, every day 2 times.
Test b group: take tablet prepared by embodiment 4, every sheet contains crude drug amount 0.25g, each 2-4 sheet, every day 2 times.
Test c group: take tablet prepared by embodiment 5, every sheet contains crude drug amount 0.25g, each 2-4 sheet, every day 2 times.
Test d group: give spasmolytic, pain relieving, correction water, electrolyte and acid-base metabolism unbalance, whole body Supporting Therapy, and selecting all effective broad ectrum antibiotic of Grain-negative, positive bacteria and anaerobe or drug combination.。
Within one week, be a course for the treatment of, after the course for the treatment of, add up therapeutic effect.
4. result of the test:
Draft with reference to Ministry of Public Health " new Chinese medicine guideline of clinical investigations " (1997) " criterion of therapeutical effect of acute cholecystitis (hypochondriac pain) ".
Cure: symptom, sign disappear completely, body temperature, routine blood test recover normal, and Type B is ultrasonic, x-ray cholecystography is normal;
Effective: symptom, sign disappear, and body temperature, routine blood test recover normal substantially, and Type B is ultrasonic, x-ray cholecystography obviously improves;
Effective: symptom, sign disappear substantially, body temperature, routine blood test are normal, and Type B is ultrasonic, x-ray cholecystography is improved;
Invalid: symptom, sign, body temperature, routine blood test, Type B are ultrasonic, x-ray cholecystography is without improvement.
Total effective rate=(cure+effective+effectively)/total number of cases × 100%.
Treatments period advises patient to forbid drinking, and fasting delicious food savoury, takes a good rest, and can not overwork.
5. statistical method
Carry out statistical analysis with statistics software SPSS20.0 to data, enumeration data adopts x
2inspection; Measurement data mean ± standard deviation
represent, carry out t inspection; P < 0.05 represents that between two groups, diversity is remarkable.
6. therapeutic outcome
1) the concrete therapeutic outcome testing each group is as shown in table 1.
Table 1: four groups for the treatment of clinical effectiveness
| Group | n | Cure | Effective | Effectively | Invalid | Effective percentage |
| Test a group | 40 | 28 | 8 | 3 | 1 | 97.5％ *◎& |
| Test b group | 40 | 15 | 10 | 6 | 9 | 77.5％ |
| Test c group | 40 | 14 | 8 | 8 | 10 | 75.0％ |
| Test d group | 40 | 12 | 11 | 5 | 12 | 70.0％ |
Note: test a group compares with test b group,
*p < 0.05; Compare with test c group,
◎p < 0.05; Compare with test b group,
aMP.AMp.Ampp < 0.05.
As can be seen from table 1 relatively, clinical cure 28 people (cure rate 70%), total effective rate 97.5% in test a group, all be better than other test group, and significant difference, there is statistical significance (P < 0.05), though respectively group curative effect is variant for other, but not there is statistical significance (P > 0.05), the clinical effectiveness particularly testing b, c group shows, random change formula and proportioning, can not reach therapeutic effect of the present invention completely.
2) before and after two groups of patient treatments, body temperature and numeration of leukocyte improvement situation compare
Before and after table 2. liang group patient treatment, body temperature and numeration of leukocyte improvement situation compare
Note: after treatment, test a group compares with test b group,
*p < 0.05; Compare with test c group,
◎p < 0.05; Compare with test b group,
aMP.AMp.Ampp < 0.05.
After each group for the treatment of, body temperature and numeration of leukocyte obviously decline (P < 0.05) before all comparatively treating, but test a group declines more remarkable, respectively organizes comparing difference all have statistical significance (P < 0.05) with other.
More than testing each group and be showed no serious adverse reaction, observing 1 year to test a group recovery from illness patient Continuous Tracking subsequently, not finding the phenomenon that case recurs.
To sum up, the invention provides a kind of Chinese medicine composition and preparation method thereof, this Traditional Chinese medicine composition formula is simple, compatibility scientific and precise, treatment acute cholecystitis effect are faster, better, have the remarkable efficacy of clearing away heat-damp and promoting diuresis, promoting the circulation of QI to relieve pain, dispersing swelling and dissipating binds.This Chinese medicine preparation, under instruction of Chinese Medicine theory, adopts high-quality, genuine medicinal materials, processes, steady quality through specification procedure, there is composition unification, taking convenience, be beneficial to carry, feature that determined curative effect, safety are higher.Illustrate that the present invention prepares pharmaceutical properties and stablizes, safety coefficient is high, thus reduce further toxic and side effects, and the method is simple, is applicable to promoting production in enormous quantities.
Claims (7)
1. be used for the treatment of a pharmaceutical composition for acute cholecystitis, it is characterized in that, described pharmaceutical composition is made up of following traditional Chinese medicines: Fructus Forsythiae, Cortex Magnoliae Officinalis(processed with ginger), Cortex Moutan, Radix Angelicae Sinensis, Herba Taraxaci, Spora Lygodii, Folium Perillae, Fructus Gardeniae.
2. pharmaceutical composition as claimed in claim 1, it is characterized in that, in described pharmaceutical composition, the parts by weight of each Chinese medicine are: Fructus Forsythiae 10-20 weight portion, Cortex Magnoliae Officinalis(processed with ginger) 2-8 weight portion, Cortex Moutan 5-15 weight portion, Radix Angelicae Sinensis 16-25 weight portion, Herba Taraxaci 6-12 weight portion, Spora Lygodii 2-6 weight portion, Folium Perillae 2-10 weight portion, Fructus Gardeniae 2-10 weight portion.
3. pharmaceutical composition as claimed in claim 1, it is characterized in that, the parts by weight of each Chinese medicine of described pharmaceutical composition are: Fructus Forsythiae 15 weight portion, Cortex Magnoliae Officinalis(processed with ginger) 5 weight portion, Cortex Moutan 10 weight portion, Radix Angelicae Sinensis 20 weight portion, Herba Taraxaci 9 weight portion, Spora Lygodii 4 weight portion, Folium Perillae 6 weight portion, Fructus Gardeniae 6 weight portion.
4. the pharmaceutical composition as described in claim 1-3, is characterized in that, described pharmaceutical composition is oral formulations.
5. pharmaceutical composition as claimed in claim 4, it is characterized in that, described oral formulations is preferably tablet, capsule etc.
6. the purposes of the medicine described in claim 1-3 in the medicine of preparation treatment acute cholecystitis.
7. the purposes of the medicine described in claim 1-3 in the medicine of preparation treatment liver gallbladder damp-heat type acute cholecystitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510944971.6A CN105326952A (en) | 2015-12-16 | 2015-12-16 | Medicine composition for treating acute cholecystitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510944971.6A CN105326952A (en) | 2015-12-16 | 2015-12-16 | Medicine composition for treating acute cholecystitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105326952A true CN105326952A (en) | 2016-02-17 |
Family
ID=55277858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510944971.6A Withdrawn CN105326952A (en) | 2015-12-16 | 2015-12-16 | Medicine composition for treating acute cholecystitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105326952A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105663431A (en) * | 2016-02-24 | 2016-06-15 | 林立朋 | Medicine composition used for clinical anesthesia and preparation method thereof |
| CN106266461A (en) * | 2016-10-12 | 2017-01-04 | 褚立旺 | A kind of Chinese medicine composition assisting treatment liver gallbladder damp-heat type acute cholecystitis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101569739A (en) * | 2009-06-19 | 2009-11-04 | 宿连湘 | Traditional Chinese medicine composition for treating cholecystitis and preparation method thereof |
| CN104771697A (en) * | 2015-04-14 | 2015-07-15 | 青岛辰达生物科技有限公司 | Pharacetuical composition for treating cholecystitis |
-
2015
- 2015-12-16 CN CN201510944971.6A patent/CN105326952A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101569739A (en) * | 2009-06-19 | 2009-11-04 | 宿连湘 | Traditional Chinese medicine composition for treating cholecystitis and preparation method thereof |
| CN104771697A (en) * | 2015-04-14 | 2015-07-15 | 青岛辰达生物科技有限公司 | Pharacetuical composition for treating cholecystitis |
Non-Patent Citations (1)
| Title |
|---|
| 孙飚: "急性胆囊炎80例中医辨证施治疗效观察", 《临床合理用药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105663431A (en) * | 2016-02-24 | 2016-06-15 | 林立朋 | Medicine composition used for clinical anesthesia and preparation method thereof |
| CN106266461A (en) * | 2016-10-12 | 2017-01-04 | 褚立旺 | A kind of Chinese medicine composition assisting treatment liver gallbladder damp-heat type acute cholecystitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104873705A (en) | Medicinal composition for treating angina pectoris of coronary heart disease and application thereof | |
| CN102847021B (en) | Enema for treating ulcerative colitis and preparation method thereof | |
| CN101032593A (en) | Acne-treating Chinese medicine preparation | |
| CN103520533B (en) | Chinese medicine for aplastic anemia | |
| CN101129672A (en) | Orally taken traditional Chinese medicine composition for treating bacillary dysentery | |
| CN102671088A (en) | Traditional Chinese medicine combination for treating tuberculosis | |
| CN105326952A (en) | Medicine composition for treating acute cholecystitis | |
| CN103055218B (en) | Traditional Chinese medicine composition for treating neonatal jaundice and preparation method thereof | |
| CN101028490A (en) | Chinese medicine for treating acne | |
| CN103893432B (en) | It is a kind of to treat fracture, pharmaceutical composition of soft tissue injury and preparation method thereof | |
| CN112168947A (en) | Traditional Chinese medicine composition for treating pneumonia and preparation method thereof | |
| CN105770074A (en) | Traditional Chinese medicine composition for treating wind-heat common cold and preparation method thereof | |
| CN105521473A (en) | Poliomyelitis sequela treatment medicine and preparation method thereof | |
| CN105327182A (en) | Medicine for treating child pertussis and preparation method thereof | |
| CN105521332A (en) | Traditional Chinese medicinal composition for treating anal fissure, and preparation method and application thereof | |
| CN105031595A (en) | Traditional Chinese medicine tablet for treating nummular eczema and preparing method thereof | |
| CN104800675A (en) | Medicament for treating active ulcerative colitis | |
| CN105056078A (en) | Traditional Chinese medicine composition for treating stomach fire exuberance, toothache and ozostomia | |
| CN102423458A (en) | Chinese patent medicine for treating psoriasis | |
| CN105147845A (en) | Traditional Chinese medicine for treating stomach fire toothache | |
| CN104491369B (en) | Medicinal composition for treating hemoptysis | |
| CN105343653A (en) | Traditional Chinese medicine preparation for treating anorectic dysentery | |
| CN104998189A (en) | Traditional Chinese medicine powder for treating infantile oral ulcer of wind-heat spleen type and preparation method thereof | |
| CN113713073A (en) | Traditional Chinese medicine composition for treating spleen and stomach damp-heat type chronic atrophic gastritis | |
| CN108969733A (en) | A kind of Chinese medicine composition and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160217 |